Cep55/c10orf3, a Tumor Antigen Derived From a Centrosome Residing Protein in Breast Carcinoma

• DOI: 10.1097/cji.0b013e3181a1d109
• Publication Date: 2009-05-21T13:24:45Z
• Authors: Satoko Inoda; Yoshihiko Hirohashi; Toshihiko Torigoe; Munehide Nakatsugawa; Kenji Kiriyama; Emiri Nakazawa; Kenji Harada; Hideo Takasu; Yasuaki Tamura; Kenjiro Kamiguchi; Hiroko Asanuma; Tetsuhiro Tsuruma; Takeshi Terui; Kunihiko Ishitani; Tosei Ohmura; Qiang Wang; Mark I. Greene; Tadashi Hasegawa; Koichi Hirata; Noriyuki Sato
• Keywords: CTL*; Breast carcinoma

Identification of tumor-associated antigens may facilitate vaccination strategies to treat patients with malignant diseases. We have found that the centrosomal protein, Cep55/c10orf3 acts as a novel breast carcinoma-associated antigen. mRNA was detectable in wide variety tumor cell lines. Expression barely normal tissues except for testis and thymus. Moreover, protein could be detected by monoclonal anti-Cep55/c10orf3 antibody (♯11-55) 69.8% carcinoma, 25% colorectal 57.8% lung carcinoma tissues. The expression did not show any relationship hormone receptors such estrogen receptor progesterone or patterns p185HER2/neu. designed 11 peptides which displayed human leukocyte antigen-A24 binding motif. One Cep55/c10orf3-peptide, Cep55/c10orf3_193(10) (VYVKGLLAKI), induced cytotoxic T lymphocytes (CTLs) 3 (♯11-55)-positive carcinoma. A Cep55/c10orf3_193(10)-specific CTL clone also recognize (+) on cancer These data indicate were naturally presented cells can cause clonal expansion vivo. Monoclonal ♯11-55 useful part therapeutic strategy hormonal therapy anti-p185HER2/neu therapy-resistant patients.